Foamlab B.V. announced that it has raised €3 million in funding to scale production of its bio-based foam materials and advance commercial deployment. The round included participation from Icos Capital, Value Factory Ventures, DOEN Ventures, Capricorn Industrial Biotech Fund, and TTT Green Tech Fund.
The funding will be used to build a pilot plant, scale manufacturing capabilities, and accelerate the commercial rollout of Foamlab’s sustainable foam materials. The company is focused on developing alternatives to traditional petroleum-based foams, which are widely used across industries but present environmental challenges.
Foamlab’s technology is based on bacterial cellulose, a natural material produced through fermentation processes. This approach enables the creation of renewable, bio-based foam materials that have the potential to reduce reliance on fossil-fuel-derived inputs while maintaining the performance characteristics required for industrial applications.
The company originated as a spin-off from Delft University of Technology, leveraging research from its Industrial Design Engineering faculty. Foamlab is positioning its materials within a broader shift toward sustainable manufacturing and circular material systems.
With the new funding, the company aims to transition from research and development to scaled production, targeting industries seeking environmentally friendly alternatives for packaging, consumer products, and industrial applications.
The investment reflects growing interest in industrial biotechnology and sustainable materials, particularly solutions that can be produced at scale and integrated into existing supply chains.
